UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT
Genmab A/S (NASDAQ:GMAB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential.
Genmab A/S (GMAB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 5,710,741 | $111,816,309 | +103% | 0.64% |
| 2. | Citadel Investment Group Ken Griffin | 4,426,654 | $86,673,885 | +44% | 0.02% |
| 3. | Renaissance Technologies Jim Simons | 2,262,350 | $44,296,813 | +18% | 0.07% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,181,510 | $42,713,967 | +95% | 0.05% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,973,700 | $38,645,046 | +20% | 0.09% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,348 | $358,410 | 0.17% | |
| 2. | 12,685 | $257,497 | 0% | |
| 3. | 12,084 | $249,655 | 0.05% | |
| 4. | 10,567 | $218,314 | 0.03% | |
| 5. | 3,720 | $76,846 | 0% |
News See All
Genmab (GMAB) Announced Results From its EPCORE NHL-2 Trial
Genmab A/S (NASDAQ:GMAB) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 15, Genmab A/S (NASDAQ:GMAB) announced results from its EPCORE NHL-2 trial, Arm 10.
10 Best Growth Stocks to Buy With Huge Upside Potential
On July 8, Tom Lee, head of research at Fundstrat, joined CNBC to discuss how the US tariffs might impact the market, economy, and inflation.
13 Cheap Healthcare Stocks with Huge Upside Potential
On July 8, Kate Moore, Citi Wealth CIO, appeared on CNBC's 'Squawk Box' to talk about the recent rally in equities.
Leerink Raises Genmab (GMAB) Price Target, Keeps Outperform Rating
The updated data showed positive results and supports the company’s aim to start a Phase 111 trial later this year.
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer
Results from the Phase 1/2 RAINFOL-01 trial, presented at the 2025 ASCO Annual Meeting, show that Rina-S 100 mg/m² administered every three weeks achieved a confirmed objective response rate (ORR) of...
Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025
Genmab A/S (NASDAQ:GMAB) announced that it will present pivotal new research from its late-stage oncology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30...
13 Most Profitable Growth Stocks to Buy Now
The growth factor in investing refers to companies that grow their revenue and earnings at rates significantly above the market.
8 Most Undervalued Healthcare Stocks to Buy According to Analysts
Healthcare prices and expenditures have been rising in the United States.
7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
Billionaire Hedge Funds
